Krista L Lanctôt

Krista L Lanctôt, PhD

Dr. Krista Lanctôt leads a large interdisciplinary research team whose work has focused on understanding how neuropsychiatric symptoms, such a mild cognitive impairment and mood disorders, interfere with cardiac rehabilitation. The overarching theme of her work is to understand the neurobiologic basis of these symptoms as risk factors for poor response, and use this information to develop targeted interventions. For example, her work has shown links between these symptoms and inflammation, oxidative stress and lipid aberrations. Dr. Lanctôt's team uses a variety of tools including neuroimaging, lipidomics, pharmacogenetics and neuropsychiatric assessments to unravel the link between dysfunction in various cellular and molecular processes and manifestation of these symptoms in a cardiac rehabilitation population. In addition, her group has run clinical trials of dietary, pharmacologic and exercise interventions for these symptoms.

Each year tens of thousands of Canadians are diagnosed with coronary artery disease (CAD) which poses a serious risk to their health and well-being. Depression and associated symptoms of cognitive impairment are common neuropsychiatric symptoms in CAD and have a major negative impact on treatment outcomes and life expectancy. Dr. Lanctôt's work has also shown their negative impact on cardiac rehabilitation outcomes. Understanding the neurobiology of these symptoms may allow us to predict response to cardiac rehabilitation and, on a broader level, may lead to the development of novel therapies.
 
Alzheimers Dement (N Y). 2017 Sep;3(3):440-449
Lanctôt KL, Amatniek J, Ancoli-Israel S, Arnold SE, Ballard C, Cohen-Mansfield J, Ismail Z, Lyketsos C, Miller DS, Musiek E, Osorio RS, Rosenberg PB, Satlin A, Steffens D, Tariot P, Bain LJ, Carrillo MC, Hendrix JA, Jurgens H, Boot B
Neurodegener Dis Manag. 2017 Oct 18;:
Liu CS, Rau A, Gallagher D, Rajji TK, Lanctôt KL, Herrmann N
Am J Geriatr Psychiatry. 2017 May 15;:
Chee JN, Rapoport MJ, Molnar F, Herrmann N, O'Neill D, Marottoli R, Mitchell S, Tant M, Dow J, Ayotte D, Lanctôt KL, McFadden R, Taylor JP, Donaghy PC, Olsen K, Classen S, Elzohairy Y, Carr DB
J Clin Exp Neuropsychol. 2017 Sep 15;:1-13
Fishman KN, Ashbaugh AR, Lanctôt KL, Cayley ML, Herrmann N, Murray BJ, Sicard M, Lien K, Sahlas DJ, Swartz RH
J Affect Disord. 2017 Aug 30;225:599-606
Sun YR, Herrmann N, Scott CJM, Black SE, Khan MM, Lanctôt KL
J Neurol Neurosurg Psychiatry. 2017 Aug 09;:
Lai KSP, Liu CS, Rau A, Lanctôt KL, Köhler CA, Pakosh M, Carvalho AF, Herrmann N
Neurobiol Aging. 2017 Jul 11;:
Swardfager W, Yu D, Scola G, Cogo-Moreira H, Chan P, Zou Y, Herrmann N, Lanctôt KL, Ramirez J, Gao F, Masellis M, Swartz RH, Sahlas DJ, Chan PC, Ojeda-Lopez C, Milan-Tomas A, Pettersen JA, Andreazza AC, Black SE
J Alzheimers Dis. 2017 Jul 17;:
Edwards JD, Ramirez J, Callahan BL, Tobe SW, Oh P, Berezuk C, Lanctôt K, Swardfager W, Nestor S, Kiss A, Strother S, Black SE, Alzheimer’s Disease Neuroimaging Initiative
Int Psychogeriatr. 2017 Jul 10;:1-11
Desmarais P, Lanctôt KL, Masellis M, Black SE, Herrmann N
Expert Opin Drug Saf. 2017 Jul 12;:1-11
Mohammad D, Chan P, Bradley J, Lanctôt K, Herrmann N

Pages


Senior Scientist, Evaluative Clinical Sciences, Hurvitz Brain Sciences Research Program, Sunnybrook Research Institute
Director, Neuropsychopharmacology Research Program, Sunnybrook Health Science Centre
Professor, Department of Psychiatry, University of Toronto
Professor, Department of Pharmacology and Toxicology, University of Toronto
Full Member, School of Graduate Studies, University of Toronto
Executive Director, MORE research group, Sunnybrook Research Institute